Stifel Nicolaus Raises LivaNova (NASDAQ:LIVN) Price Target to $72.00

LivaNova (NASDAQ:LIVN) had its price target increased by Stifel Nicolaus from $70.00 to $72.00 in a research note issued to investors on Thursday, Benzinga reports. They currently have a buy rating on the stock.

Several other analysts have also recently weighed in on the stock. Needham & Company LLC reiterated a buy rating and issued a $72.00 price target on shares of LivaNova in a report on Thursday, June 6th. Mizuho increased their price target on shares of LivaNova from $75.00 to $80.00 and gave the stock a buy rating in a research note on Thursday, May 2nd. StockNews.com raised LivaNova from a hold rating to a buy rating in a research report on Thursday, April 25th. Finally, Robert W. Baird increased their target price on LivaNova from $58.00 to $66.00 and gave the stock a neutral rating in a research report on Thursday, May 2nd. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average price target of $67.17.

LivaNova Price Performance

Shares of LivaNova stock opened at $53.61 on Thursday. The company’s fifty day simple moving average is $55.07 and its two-hundred day simple moving average is $54.47. LivaNova has a 12-month low of $42.75 and a 12-month high of $64.47. The firm has a market cap of $2.90 billion, a PE ratio of -89.35 and a beta of 0.99. The company has a quick ratio of 2.71, a current ratio of 3.17 and a debt-to-equity ratio of 0.50.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.28. The company had revenue of $294.90 million for the quarter, compared to analysts’ expectations of $278.17 million. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. LivaNova’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period last year, the firm earned $0.43 earnings per share. As a group, equities analysts expect that LivaNova will post 2.6 EPS for the current year.

Insider Activity at LivaNova

In other LivaNova news, Director Daniel Jeffrey Moore sold 56,623 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $60.11, for a total value of $3,403,608.53. Following the sale, the director now directly owns 27,534 shares of the company’s stock, valued at $1,655,068.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.27% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LivaNova

Institutional investors and hedge funds have recently modified their holdings of the stock. Norges Bank purchased a new stake in shares of LivaNova during the fourth quarter valued at approximately $26,064,000. Mesirow Institutional Investment Management Inc. bought a new stake in shares of LivaNova in the 1st quarter worth $13,816,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of LivaNova in the fourth quarter worth $8,330,000. Magnetar Financial LLC lifted its holdings in shares of LivaNova by 24.5% during the first quarter. Magnetar Financial LLC now owns 753,338 shares of the company’s stock valued at $42,142,000 after purchasing an additional 148,178 shares in the last quarter. Finally, abrdn plc purchased a new stake in shares of LivaNova during the fourth quarter valued at $5,613,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.